HUTCHMED (China) Limited
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsHUTCHMED (China) Ltd is a pharmaceutical company focused on oncology and immunology, with additional ventures in other therapeutic areas, reporting $548.5 million in revenue and $456.9 million in net income for 2025.
What they do
HUTCHMED discovers, develops, and commercializes pharmaceutical products, primarily in oncology and immunology. The company generates revenue through product sales, licensing and collaboration agreements, and manufacturing and supply services. It operates through segments including Oncology/Immunology and Other Ventures, which includes goods distribution. Key collaboration partners include Takeda, AstraZeneca, and Eli Lilly.
Revenue drivers
- Oncology/Immunology segment — This segment generates revenue from marketed products, licensing and collaborations, and commercialization services. It is the primary revenue source, with revenue from marketed products and collaborations with partners such as Takeda and AstraZeneca.
- Licensing and collaboration revenue — Revenue from upfront payments, milestone payments, and royalties under agreements with partners like Takeda, AstraZeneca, and Eli Lilly. This includes licensing from upfront payments and research and development services.
- Other Ventures segment — This segment primarily consists of goods distribution and other non-core activities, generating revenue through distribution services.
- Manufacturing and supply — Revenue from manufacturing supply invoiced to partners for marketed products, particularly under the Takeda collaboration.
Recent performance
In 2025, HUTCHMED reported revenue of $548.5 million, a decrease from $630.2 million in 2024. Net income was $456.9 million, up significantly from $37.7 million in 2024, largely due to non-operating income items. Diluted EPS was $0.52 in 2025 compared to $0.04 in 2024. Operating cash flow was negative $64.7 million in 2025, a decline from positive $497 thousand in 2024. The company's cash and equivalents stood at $71.3 million at year-end 2025.
Strategy
HUTCHMED's strategy focuses on advancing its oncology and immunology pipeline, expanding global collaborations, and commercializing its products. The company continues to invest in research and development, as reflected in its collaboration agreements and licensing activities. It aims to leverage partnerships with companies like Takeda and AstraZeneca to maximize the potential of its drug candidates. Additionally, HUTCHMED maintains a presence in other ventures, such as goods distribution, to support its overall business.
Risks
- Dependence on collaboration partners — A significant portion of revenue comes from a few key partners like Takeda and AstraZeneca, and the loss of any such partner could materially impact financial results.
- Revenue concentration — Revenue is concentrated in the Oncology/Immunology segment, making the company vulnerable to fluctuations in that market or regulatory changes.
- Operating cash flow volatility — Operating cash flow turned negative in 2025 at -$64.7 million, which could strain liquidity if sustained.
- Regulatory and development risks — Pharmaceutical development is subject to regulatory approvals and clinical trial outcomes that could delay or prevent commercialization of pipeline products.
Outlook
Management has not provided specific forward guidance in the excerpt. The company's future performance will depend on the success of its oncology and immunology products, the progress of its collaborations, and its ability to manage costs and cash flow. Continued investment in R&D and potential new licensing deals may drive growth.